×
About 1,058 results

ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Research & Reviews  373 results

Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents...
https://doi.org/10.1016/j.jcv.2022.105324
Journal of Clinical Virology : the Official Publication O... Sagara Y, Nakamura H et. al.

Nov 13th, 2022 - Human T-cell leukemia virus type 1 (HTLV-1) is a causative agent of the life-threatening diseases, adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy. Following implementation of antenatal screening in Japan, novel transmission of HTL...

The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) ...
https://doi.org/10.1371/journal.pntd.0010807
PLoS Neglected Tropical Diseases; Oliveira PD, Ribeiro GS et. al.

Oct 20th, 2022 - Adult T-cell leukemia/lymphoma (ATLL), a peripheral T-cell leukemia/lymphoma associated with the human T-cell lymphotropic virus type-1 (HTLV-1), has been classified following the clinical forms defined by Shimoyama in 1991. A suggestion to modify...

Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell li...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571424
BMC Cancer; Suzuki S, Hourai S et. al.

Oct 16th, 2022 - Activated mutations in NOTCH1 are drivers of T-cell type acute lymphoblastic leukemia/lymphoma. The γ-secretase inhibitor (GSI), which suppresses the function of NOTCH1, is expected to be a molecular-targeted agent. NOTCH1 is also expressed in oth...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Oct 14th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
https://clinicaltrials.gov/ct2/show/NCT04703192

Oct 6th, 2022 - This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (B...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  18 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Oct 14th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
https://clinicaltrials.gov/ct2/show/NCT04703192

Oct 6th, 2022 - This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (B...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Oct 5th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

Study of Lacutamab in Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04984837

Aug 19th, 2022 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

see more →

News  31 results

Japan Green Lights Valemetostat Tosilate for Relapsed/Refractory Adult T-cell Leukemia/Lymphoma
https://www.onclive.com/view/japan-green-lights-valemetostat-tosilate-for-relapsed-refractory-adult-t-cell-leukemia-lymphoma

Sep 26th, 2022 - The Japan Ministry of Health, Labor and Welfare (MHLW) has approved valemetostat tosilate (Ezharmia; DS-3201b) for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL).1 The regulatory decision was based on r...

Dr. Zain on Investigational Approaches in Peripheral T-Cell Lymphoma
https://www.onclive.com/view/dr-zain-on-investigational-approaches-in-peripheral-tcell-lymphoma

Oct 6th, 2021 - Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma....

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL
https://www.onclive.com/view/remaining-echelon-2-questions-spark-novel-research-efforts-in-ptcl

Feb 17th, 2021 - Questions from the phase 3 ECHELON-2 trial (NCT01777152), which led to the 2018 FDA approval of brentuximab vedotin (Adcetris) plus chemotherapy for patients with CD30-expressing peripheral T-cell lymphoma (PTCL), have given way to additional rese...

An International Experience at Home
https://www.onclive.com/view/an-international-experience-at-home

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

Interferon Therapy: A Growing Family Feeds New Interest in an Older Treatment
https://www.onclive.com/view/interferon-therapy-a-growing-family-feeds-new-interest-in-an-older-treatment

Dec 5th, 2020 - More than half a century has passed since interferons (IFNs) were first discovered. Since then, they have evolved from a cure-all for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of differen...

see more →